Drug

Enoxaparin

Approved · EMA

ClassAntithrombin-III activatorEmerging researchLate-stage developmentSteady momentum

Also known as Lovenox, Énoxaparine, Enoxaparin Sodium.

RxNorm67108 ChEMBLCHEMBL1201476 ATCB01AB05UNIIE47C0NF7LV

Research papers

Active clinical trials

Antithrombin-III

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Prospective, Randomised Controlled Trial Comparing Weight-based Tinzaparin Versus Weight-based Enoxaparin for Peri-operative Thromboprophylaxis in Patients Undergoing Bariatric Surgery: Evaluation of Anti-Xa Levels and Clinical Outcomes.

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Low Molecular Weight Heparin for the Treatment of Early Fetal Growth Restriction

Clinical trial2026-07-30Primary completion · ClinicalTrials.gov

A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active Controlled Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing Elective Primary Unilateral Total Knee Arthroplasty

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Further Characterize Andexanet Posology and Assess the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

Clinical trial2026-06-22Completed · ClinicalTrials.gov

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP)

Clinical trial2026-05-26Results expected Q2 2034 · ClinicalTrials.gov

Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial

Clinical trial2026-04-29Results expected Q2 2028 · ClinicalTrials.gov

Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction With Oligohydramnios.

Clinical trial2026-03-10Results expected Q3 2026 · ClinicalTrials.gov

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.

Research2021-02-01Blood advances

Approval: Inhixa (EMA)

Regulatory2016-09-15EMA

Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.

Research2014-06-26Circulation

D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.

Research2014-04-01Journal of thrombosis and haemostasis : JTH

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Research2013-02-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Enoxaparin

Aliases & brands

LovenoxÉnoxaparineEnoxaparin Sodium

RxNorm CUI

67108

ChEMBL ID

CHEMBL1201476

ATC codes

B01AB05

UNII

E47C0NF7LV

Primary mechanism

Antithrombin-III activator

Regulatory jurisdictions

ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Antithrombin-III

SERPINC1 · P01008

ACTIVATORAntithrombin-III activator

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2016-09-15

Latest approval

2016-09-15

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2016-09-15Approval

Approval: Inhixa (EMA)

Indication: Inhixa is indicated for adults for: Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery. Prophylaxis of venous… Show full indication

Inhixa is indicated for adults for: Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery. Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL). Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism. Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA). Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL). Blood clot prevention in the extracorporeal circulation during haemodialysis.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.